SCHEMBL4756624

SCHEMBL4756624

CN1C(=O)N(C)C2(CCN(CCc3ccc(C(N)=O)cc3)CC2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 3/20 0.46
ITGA2B P08514 3/20 0.46
OPRM1 P35372 7/20 0.42
OPRD1 P41143 2/20 0.42
OPRK1 P41145 2/20 0.42
ARRB1 P49407 2/20 0.40
MAOB P27338 1/20 0.40
KCNH2 Q12809 3/20 0.38
KCNJ1 P48048 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR7 P34969 1/20 0.38
HTR6 P50406 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4756628 0.85 SIGMAR1 (0.45) ITGB3ITGA2BOPRM1KCNH2KCNJ1
SCHEMBL4965100 0.80 OPRM1 (0.43) OPRM1OPRD1OPRK1ARRB1MAOB
SCHEMBL4699834 0.75 SIGMAR1 (0.50) MAOBKCNH2KCNJ1HTR2AHTR2C
SCHEMBL6644138 0.74 HRH3 (0.58) MAOBKCNH2HTR2AHTR2CHTR7
SCHEMBL2761915 0.73 HRH3 (0.61) MAOBHTR2AHTR2CHTR7HTR6
SCHEMBL2762023 0.73 HRH3 (0.61) MAOBHTR2AHTR2CHTR7HTR6
SCHEMBL4700447 0.72 TSHR (0.48) MAOBKCNH2KCNJ1HTR2AHTR2C
SCHEMBL4699855 0.72 KDM1A (0.43) OPRM1OPRD1OPRK1MAOBKCNH2
SCHEMBL3514227 0.71 THRA (0.53) HTR2AHTR2CHTR7HTR6SIGMAR1
SCHEMBL4703775 0.70 KCNH2 (0.43) OPRM1ARRB1MAOBKCNH2KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 US disclosed
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-08-28 US disclosed
EP-1960382-A1 HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS ChemBridge Research Laboratories, Inc. (US) 2008-08-27 EP disclosed
WO-2007056155-A1 HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders LCK, MALT1, MYD88 ITGB3 2893/4885ITGA2B 2562/4885OPRM1 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.